Score | Cases | Controls | RR | 95% CI | P value | ||
---|---|---|---|---|---|---|---|
Tamoxifen treated (55 cases and 150 controls) | |||||||
Multivariate analyses without Recurrence Score1 | Â | Â | Â | Â | Â | Â | Â |
   Tumor size (cm) |  |  |  |  |  |  | 0.009 |
Continuous2 | 55 | (100%) | 150 | (100%) | 2.6 | (1.2–5.5) |  |
   Grade (pathologist 1) |  |  |  |  |  |  | 0.007 |
Well | 6 | (11%) | 50 | (33%) | 1.0 | reference | Â |
Moderate | 28 | (51%) | 69 | (46%) | 2.8 | (1.1–7.4) |  |
Poor | 21 | (38%) | 31 | (21%) | 4.5 | (1.6–12.3) |  |
Multivariate analyses with Recurrence Score3 | |||||||
   Tumor size (cm) |  |  |  |  |  |  | 0.013 |
Continuous2 | 55 | (100%) | 150 | (100%) | 2.5 | (1.2–5.4) |  |
   Grade (pathologist 1) |  |  |  |  |  |  | 0.126 |
Well | 6 | (11%) | 50 | (33%) | 1.0 | reference | Â |
Moderate | 28 | (51%) | 69 | (46%) | 2.4 | (0.9–6.4) |  |
Poor | 21 | (38%) | 31 | (21%) | 2.8 | (0.9–9.3) |  |
   Recurrence Score |  |  |  |  |  |  | 0.003 |
Continuous4 | 55 | (100%) | 150 | (100%) | 5.3 | (1.6–17.2) |  |
Tamoxifen untreated (110 cases and 251 controls) | |||||||
Multivariate analyses without Recurrence Score1 | |||||||
   Tumor size (cm) |  |  |  |  |  |  | 0.035 |
Continuous2 | 110 | (100%) | 251 | (100%) | 1.8 | (1.0–3.1) |  |
   Grade (pathologist 1) |  |  |  |  |  |  | <0.001 |
Well | 17 | (15%) | 83 | (33%) | 1.0 | reference | Â |
Moderate | 54 | (49%) | 131 | (52%) | 2.0 | (1.1–3.6) |  |
Poor | 39 | (35%) | 37 | (15%) | 4.7 | (2.3–9.9) |  |
Multivariate analyses with Recurrence Score3 | |||||||
   Tumor size (cm) |  |  |  |  |  |  | 0.036 |
Continuous2 | 110 | (100%) | 251 | (100%) | 1.8 | (1.0–3.1) |  |
   Grade (pathologist 1) |  |  |  |  |  |  | 0.018 |
Well | 17 | (15%) | 83 | (33%) | 1.0 | reference | Â |
Moderate | 54 | (49%) | 131 | (52%) | 1.8 | (1.0–3.4) |  |
Poor | 39 | (35%) | 37 | (15%) | 3.2 | (1.4–7.2) |  |
   Recurrence Score |  |  |  |  |  |  | 0.025 |
Continuous4 | 110 | (100%) | 251 | (100%) | 2.4 | (1.1–5.2) |  |